Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.
